nedometinib   Click here for help

GtoPdb Ligand ID: 12872

Synonyms: Example 2 [US11161845B2] | NFX-179 | NFX179
Compound class: Synthetic organic
Comment: The structure for nedometinib was obtained from proposed INN list 129 (August 2023) where it is described as tyrosine kinase inhibitor and antineoplastic agent. It is likely NFlection Therapeutics' topical MEK inhibitor NFX-179 [1]. MEK inhibitors are exploited to block signalling through the Ras-MAPK cascade that is activated in NF1 mutant positive neurofibromas.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 86.19
Molecular weight 470.24
XLogP 1.98
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1C2=C(C=CC=N2)C(=C1NC3=CC=C(C=C3F)I)C(=O)NOCCO
Isomeric SMILES CN1C2=C(C=CC=N2)C(=C1NC3=C(C=C(C=C3)I)F)C(=O)NOCCO
InChI InChI=1S/C17H16FIN4O3/c1-23-15-11(3-2-6-20-15)14(17(25)22-26-8-7-24)16(23)21-13-5-4-10(19)9-12(13)18/h2-6,9,21,24H,7-8H2,1H3,(H,22,25)
InChI Key SENAOZROGSYRTD-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
NFX-179 is under development for the treatment of neurofibromatosis 1 (NF1) and cutaneous neurofibromas (cNF).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05005845 NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Phase 2 Interventional NFlection Therapeutics, Inc.
NCT04435665 NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Phase 2 Interventional NFlection Therapeutics, Inc.
NCT05195762 12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi Phase 2 Interventional Stanford University